This data set represents the best estimates of WHO using methodologies for specific indicators that aim for comparability across countries and time; they are updated as more recent or revised data become available, or when there are changes to the methodology being used. Therefore, they are not alwa...ys the same as official national estimates, although WHO whenever possible will provide Member States the opportunity to review and comment on data and estimates as part of country consultations. Note that these numbers are subject to change due to ongoing reclassification, retrospective investigation and availability of laboratory results. Please check the Indicator and Measurement Registry for indicator specific information.
In this section you will find data and statisticss:
Countries with intense transmission
Other affected countries
Download most recent available data
more
Hover over the image for an interactive guide to our Ebola teams' Personal Protective Equipment: http://www.msf.org/article/interactive-learn-about-our-ebola-protective-equipment
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The document summarizes the infrastructure and activities for Ebola virus disease (EVD) preparedness that are already in place in the Gambia and identifies opportunities for improvement to strengthen the nation’s readiness in the event of an EVD incident.
Bolkan HA, Bash-Taqi DA, Samai M, Gerdin M, von Schreeb J. Ebola and Indirect Effects on Health Service Function in Sierra Leone. PLOS Currents Outbreaks. 2014 Dec 19. Edition 1. doi: 10.1371/currents.outbreaks.0307d588df619f9c9447f8ead5b72b2d.
Inpatient health services have been severely affecte...d by the Ebola outbreak. The dramatic documented decline in facility inpatient admissions and major surgery is likely to be an underestimation. Reestablishing such care is urgent and must be a priority.
more
The immediate objective of the country visit to Cameroon was to ensure that the country is as operationally ready as possible to effectively and safely detect, investigate and report potential Ebola virus disease cases and to mount an effective response that will prevent a larger outbreak. After te...chnical working group meetings, field visits, a “table-top” exercise and a hospital-based simulation exercises were undertaken.
Key strengths and weaknesses were identified, and the following areas for improvement were proposed to the Ministry of Health: coordination, surveillance, contact tracing, infection prevention and control, rapid response teams, case management, social mobilization, laboratory, points of entry, budget, logistics.
more
Here you can download Posters in English, French and Portuguese